Literature DB >> 8288578

Growth state- and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase.

K Kimura1, M Saijo, M Ui, T Enomoto.   

Abstract

The fluctuations in the expression of two forms of DNA topoisomerase II, p170 and p180, were examined by immunoblotting during the transition of the growth state and the cell cycle in Swiss 3T3 cells. The level of p170 expression was higher during the exponentially growing phase than in the stationary phase, and the level of p180 did not appear to change when the cells changed the growth state. When quiescent cells were stimulated with serum, the p170 level began to increase at 12 h and reached a maximal level at 24-28 h, corresponding to the G2 phase. In contrast, the level of p180 was almost constant during the cell cycle, and the p180 band became obscure when the number of mitotic cells increased. Immunoblotting of the samples prepared from metaphase-synchronized HeLa cells did not have a p180 band, but did exhibit a band with a higher molecular weight. This band increased and p180 decreased in parallel with the increase in the number of mitotic cells. When the cells exited from the M phase, p180 reappeared and the higher molecular weight band disappeared.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8288578

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  Sp1 mediates cell proliferation-dependent regulation of rat DNA topoisomerase IIalpha gene promoter.

Authors:  J H Yoon; J K Kim; G B Rha; M Oh; S H Park; R H Seong; S H Hong; S D Park
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

2.  Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain.

Authors:  N Adachi; M Miyaike; S Kato; R Kanamaru; H Koyama; A Kikuchi
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

3.  Protein kinase C delta activates topoisomerase IIalpha to induce apoptotic cell death in response to DNA damage.

Authors:  Kiyotsugu Yoshida; Tomoko Yamaguchi; Hirokuni Shinagawa; Naoe Taira; Keiichi I Nakayama; Yoshio Miki
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

4.  Functional interaction between human topoisomerase IIalpha and retinoblastoma protein.

Authors:  U G Bhat; P Raychaudhuri; W T Beck
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 5.  Structure and function of type II DNA topoisomerases.

Authors:  P M Watt; I D Hickson
Journal:  Biochem J       Date:  1994-11-01       Impact factor: 3.857

6.  Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: a potential chemotherapeutic target.

Authors:  Mitsutsune Washiro; Masayuki Ohtsuka; Fumio Kimura; Hiroaki Shimizu; Hiroyuki Yoshidome; Takashi Sugimoto; Naohiko Seki; Masaru Miyazaki
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-17       Impact factor: 4.553

7.  Transient dsDNA breaks during pre-replication complex assembly.

Authors:  Emmanouil Rampakakis; Maria Zannis-Hadjopoulos
Journal:  Nucleic Acids Res       Date:  2009-07-28       Impact factor: 16.971

8.  Use of divalent metal ions in the dna cleavage reaction of human type II topoisomerases.

Authors:  Joseph E Deweese; Amber M Burch; Alex B Burgin; Neil Osheroff
Journal:  Biochemistry       Date:  2009-03-10       Impact factor: 3.162

9.  Vaccinia virus DNA ligase recruits cellular topoisomerase II to sites of viral replication and assembly.

Authors:  Y-C James Lin; Jianhong Li; Chad R Irwin; Heather Jenkins; Luke DeLange; David H Evans
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

10.  Deletion of Forkhead Box M1 transcription factor from respiratory epithelial cells inhibits pulmonary tumorigenesis.

Authors:  I-Ching Wang; Lucille Meliton; Xiaomeng Ren; Yufang Zhang; David Balli; Jonathan Snyder; Jeffrey A Whitsett; Vladimir V Kalinichenko; Tanya V Kalin
Journal:  PLoS One       Date:  2009-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.